| Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities ME Lacouture, MJ Anadkat, RJ Bensadoun, J Bryce, A Chan, JB Epstein, ... Supportive Care in Cancer 19 (8), 1079-1095, 2011 | 524 | 2011 |
| Symptomatic toxicities experienced during anticancer treatment: agreement between patient and physician reporting in three randomized trials M Di Maio, C Gallo, NB Leighl, MC Piccirillo, G Daniele, F Nuzzo, ... | 479 | 2015 |
| Clinical practice guidelines for the prevention and treatment of acute and late radiation reactions from the MASCC Skin Toxicity Study Group RKS Wong, RJ Bensadoun, CB Boers-Doets, J Bryce, A Chan, JB Epstein, ... Supportive Care in Cancer 21 (10), 2933-2948, 2013 | 294 | 2013 |
| Patient-reported outcomes in the evaluation of toxicity of anticancer treatments M Di Maio, E Basch, J Bryce, F Perrone Nature reviews Clinical oncology 13 (5), 319-325, 2016 | 246 | 2016 |
| Vandetanib (ZD6474), a dual inhibitor of vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) tyrosine kinases: current status and … A Morabito, MC Piccirillo, F Falasconi, G De Feo, A Del Giudice, J Bryce, ... The oncologist 14 (4), 378-390, 2009 | 239 | 2009 |
| Gynecologic Cancer InterGroup (GCIG) consensus review for clear cell carcinoma of the ovary A Okamoto, RM Glasspool, S Mabuchi, N Matsumura, H Nomura, ... International Journal of Gynecologic Cancer 24 (Supp 3), 2014 | 140 | 2014 |
| Farnesyl transferase inhibitors in clinical development F Caponigro, M Casale, J Bryce Expert opinion on investigational drugs 12 (6), 943-954, 2003 | 137 | 2003 |
| The association of financial difficulties with clinical outcomes in cancer patients: secondary analysis of 16 academic prospective clinical trials conducted in Italy F Perrone, C Jommi, M Di Maio, A Gimigliano, C Gridelli, S Pignata, ... Annals of oncology 27 (12), 2224-2229, 2016 | 135 | 2016 |
| Guidance statement on BRCA1/2 tumor testing in ovarian cancer patients E Capoluongo, G Ellison, JA López-Guerrero, F Penault-Llorca, ... Seminars in oncology 44 (3), 187-197, 2017 | 101 | 2017 |
| Randomized controlled trial testing the efficacy of platinum-free interval prolongation in advanced ovarian cancer: the MITO-8, MaNGO, BGOG-Ov1, AGO-Ovar2. 16, ENGOT-Ov1, GCIG … S Pignata, G Scambia, A Bologna, S Signoriello, IB Vergote, U Wagner, ... Journal of Clinical Oncology 35 (29), 3347-3353, 2017 | 90 | 2017 |
| Gynecologic Cancer InterGroup (GCIG) consensus review for clear cell carcinoma of the uterine corpus and cervix K Hasegawa, S Nagao, M Yasuda, D Millan, AN Viswanathan, ... International Journal of Gynecologic Cancer 24 (Supp 3), 2014 | 71 | 2014 |
| Inhibition of stromal CXCR4 impairs development of lung metastases C D’Alterio, A Barbieri, L Portella, G Palma, M Polimeno, A Riccio, ... Cancer Immunology, Immunotherapy 61 (10), 1713-1720, 2012 | 70 | 2012 |
| Phase I study of Caelyx (doxorubicin HCL, pegylated liposomal) in recurrent or metastatic head and neck cancer F Caponigro, P Cornelia, A Budillon, J Bryce, A Avallone, V De Rosa, ... Annals of oncology 11 (3), 339-342, 2000 | 61 | 2000 |
| Gefitinib in non small cell lung cancer R Costanzo, MC Piccirillo, C Sandomenico, G Carillio, A Montanino, ... Journal of Biomedicine and Biotechnology 2011, 2011 | 55 | 2011 |
| Vandetanib: an overview of its clinical development in NSCLC and other tumors A Morabito, MC Piccirillo, R Costanzo, C Sandomenico, G Carillio, ... Drugs of Today 46 (9), 683, 2010 | 54 | 2010 |
| Cancer-related fatigue in Italian cancer patients: validation of the Italian version of the Brief Fatigue Inventory (BFI) G Catania, C Bell, S Ottonelli, M Marchetti, J Bryce, A Grossi, M Costantini Supportive Care in Cancer 21 (2), 413-419, 2013 | 49 | 2013 |
| Measuring what matters MOST: validation of the Measure of Ovarian Symptoms and Treatment, a patient-reported outcome measure of symptom burden and impact of chemotherapy in … MT King, MR Stockler, RL O’Connell, L Buizen, F Joly, A Lanceley, ... Quality of Life Research 27 (1), 59-74, 2018 | 48 | 2018 |
| Cetuximab in non-small-cell lung cancer G Carillio, A Montanino, R Costanzo, C Sandomenico, MC Piccirillo, ... Expert review of anticancer therapy 12 (2), 163-175, 2012 | 40 | 2012 |
| A systematic review of patient-reported outcome instruments of dermatologic adverse events associated with targeted cancer therapies A Chan, MC Cameron, B Garden, CB Boers-Doets, K Schindler, ... Supportive Care in Cancer 23 (8), 2231-2244, 2015 | 36 | 2015 |
| CXCR4-CXCL12 and VEGF correlate to uveal melanoma progression R Franco, G Botti, M Mascolo, G Loquercio, G Liguori, G Ilardi, S Losito, ... Front Biosci (Elite Ed) 2, 13-21, 2010 | 34 | 2010 |
